Evicenter
Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer
Manufacturer
Lilly USA, LLC
Prescribing information
Verzenio (opens in a new tab)
Questions
27
Last updated

All questions

Clinical trials: Verzenio (abemaciclib) in HR-positive HER2-negative early breast cancer

9 questions · 4 sources

Clinical trials

How was the Verzenio monarchE trial designed?

Who was enrolled in the Verzenio monarchE trial (Cohort 1)?

Outcome measures

What does IDFS mean in the Verzenio monarchE trial?

Study results

What were the 7-year IDFS results with Verzenio in monarchE?

In monarchE, how many were recurrence-free at 4 years with Verzenio vs ET alone?

Note: Table 18 columns are Verzenio plus tamoxifen or an aromatase inhibitor (N=2555) and tamoxifen or an aromatase inhibitor alone (N=2565), in that order.

What were Verzenio overall survival results vs endocrine therapy alone in monarchE?

What were the 7-year distant relapse-free survival results with Verzenio in monarchE?

What did monarchE show about IDFS after Verzenio dose reductions?

Note: The dosing page of the Verzenio HCP site cites Goetz et al., NPJ Breast Cancer 2024, for the monarchE dose-reduction analysis.

Long-term data

Did Verzenio safety change at the monarchE 5-year analysis?

Note: Tables 8 and 9 of the Prescribing Information give the monarchE adverse reaction and laboratory rates.